325 Vassar Street, Suite 2B
Cambridge, MA 02139
Tel: (877) 441-4374
About Cygnal Therapeutics
Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology.
From cancer to gut inflammation and other areas of disease, nerves function in ways far beyond canonical contexts and mechanisms. The tissues they permeate make use of biochemical neural pathways and signals, and many non-neuronal cells communicate with and mimic nerves in disease settings. This is a novel way of thinking about neural signaling as outside—or exo—traditional neurobiology.
Exoneural biology is broadly implicated in human health and disease. Fueled by our dynamic Exoneural Medicine Platform™, we are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.
5 articles with Cygnal Therapeutics
9/18/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Cygnal Therapeutics Expands Leadership Team with Appointment of John A. Wagner, M.D., Ph.D., as Chief Medical Officer
Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology , announced today that John A. Wagner , M.D., Ph.D., has joined the company as chief medical officer (CMO). Since unveiling in 2019 , Cygnal has deepened its executive and scientific leadership. Dr. Wagner is th
Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology , today announced that Pearl Huang, Ph.D., President and Chief Executive Officer, will present a company overview as part of Wells Fargo's 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 at 3:
Cygnal Therapeutics Leader and Scientific Advisory Board Members Co-Author Paper in Cell Alongside Cancer Science Experts
Cygnal Therapeutics today announced the publication of a new article in Cell, titled "Roadmap for the Emerging Field of Cancer Neuroscience." Jonathan Hurov, Ph.D., who serves as Cygnal's vice president of discovery biology and platforms, and multiple members of Cygnal's Scientific Advisory Board are co-authors on the paper, among other scientists.
As the biopharma industry responds to the COVID-19 pandemic, some of the area's companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here's a look.